Google
Trusted Resources: News & Events
Latest announcements and gatherings
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Crisis
SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC) related to SCD, according to research presented at the 11th Annual Symposium of the Foundation for Sickle Cell Disease Research (FSCDR) in Fort Lauderdale, Fla.
+myBinderRelated Content
-
Cardiovascular Complications and Risk of Death in Sickle-cell DiseaseIn sickle-cell disease, a point mutation...
-
World’s Largest Sickle Cell Disease Stem Cell Library UnderwayScientists in Boston are creating a stem...
-
Cerebrovascular Accident in Sickle Cell AnemiaCerebrovascular Accident in Sickle Cell ...
-
The Role of Sleep Impairments on Pain Severity in Adults With Sickle Cell DiseaseSleep is a complex process and impairmen...
-
Jazz’ Journey With Sickle Cellhttps://www.youtube.com/watch?v=OMC5wOyD...
-
Today’s Faces of Sickle Cell Disease: Deidra Flowers-WilliamsAt six months of age, Deidra Flowers-Wil...
-
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.